To evaluate the relationships between the serum concentration of Erlotinib and the effects and toxicities of them

To evaluate the relationships between the serum concentration of Erlotinib and the effects and toxicities of them - To evaluate the relationships between the serum concentration of Erlotinib and the effects and toxicities of them

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012831

Enrollment

Registered

2014-01-12

Start date

2014-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-squamous non-small cell lung cancer

Interventions

erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) non squamous non small cell lung cancer harboring EGFR mutation 2) StageIIIB or VI 3) EGFR-TKI naive 4) ECOG PS 0-2 5) Measurable lesions (RECIST) 6) Age>=20years 7) Adequate function of main organ 8) Provided written informed consent

Exclusion criteria

Exclusion criteria: 1) severe cardiac effusion 2) severe SVC syndrome 3) severe complications 4) severe cardiac diseases 5) severe diabetes mellitus or hypertension 6) severe infections 7) Interstitial pneumonia or pulmonary fibrosis on chest CT scans 8)history of drug allergy 9)pregnant or or lactating women or those who declined contraception 10)those judged not suitable by the attending physician

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Response Rate, Overall survival, Progression-free survival, QOL	—

Countries

Japan

Contacts

Public ContactTakaya Ikeda

Nagasaki Thoracic Oncology Group Nagasaki Thoracic Oncology Group

ikedat@hospital.sasebo.nagasaki.jp0956-24-1515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026